ETAO International Co., Ltd. (ETAO) Stock Analysis
DELISTED 2024
What happened to ETAO International Co., Ltd. (ETAO) stock?
ETAO International Co., Ltd. (ETAO) no longer trades on public markets. It was delisted in May 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ETAO International Co., Ltd. (ETAO) trades at $1.91. ETAO International Co. , Ltd. is a digital healthcare company focused on providing medical care and biomedical technologies to patients in China. Market cap: $9.78M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for ETAO: ETAO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ETAO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ETAO: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →ETAO International Co., Ltd. (ETAO) Healthcare & Pipeline Overview
ETAO International Co., Ltd. operates in the digital healthcare space, focusing on the Chinese market by developing an ecosystem of medical services, including hospitals, AI diagnostics, and insurance. The company's current challenge is achieving profitability, as reflected in its negative profit margin.
What Is the Investment Thesis for ETAO?
ETAO International Co., Ltd. presents a high-risk, high-reward investment opportunity within the Chinese digital healthcare market. The company's strategy of building an integrated healthcare ecosystem, including hospitals, clinics, and AI-driven diagnostics, could address significant unmet needs in the Chinese healthcare system. However, the company's negative profit margin of -1544.4% raises concerns about its financial sustainability. Key catalysts include the successful integration of its various service offerings and expansion within the Chinese market. The company's beta of 1.92 indicates high volatility, reflecting the speculative nature of its growth prospects. Investors should carefully consider the risks associated with ETAO's financial performance and competitive landscape before investing.
Based on FMP financials and quantitative analysis
ETAO Key Highlights
Market capitalization of $9.78M indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit margin of -1544.4% highlights significant challenges in achieving sustainable profitability.
- Gross margin of 32.7% suggests potential for profitability if operating expenses can be managed effectively.
- Beta of 1.92 indicates higher volatility compared to the overall market.
Who Are ETAO's Competitors?
ETAO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APGN Apexigen, Inc. | $0.39 | +8.48% | $9.57M | 44 |
| CANO Cano Health, Inc. | $2.30 | -2.13% | $12.4M | 52 |
| CJJD China Jo-Jo Drugstores, Inc. | $1.52 | -5.59% | $9.95M | 42 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| CYCC Cyclacel Pharmaceuticals, Inc. | $6.37 | -5.98% | $10.6M | 43 |
| CMPD CompuMed, Inc. | $7.25 | -7.70% | $9.35M | 60 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ETAO's Key Strengths?
Integrated healthcare ecosystem.
- Focus on the large and growing Chinese market.
- Use of AI and big data for diagnostics.
- Insurance agency to facilitate access to services.
What Are ETAO's Weaknesses?
Significant negative profit margin.
- Limited operating history.
- High beta indicating volatility.
- Dependence on the Chinese market.
What Could Drive ETAO Stock Higher?
Successful integration of AI-driven diagnostics into the healthcare ecosystem, improving diagnostic accuracy and efficiency.
- Expansion of the insurance agency to cover a larger portion of ETAO's healthcare services, increasing patient access.
- Development and commercialization of new therapies through partnerships with biotechnology companies.
- Geographic expansion into underserved areas of China, increasing market reach and revenue potential.
What Are the Key Risks for ETAO?
Significant negative profit margin poses a risk to the company's financial sustainability.
- Intense competition in the Chinese healthcare market could limit ETAO's ability to gain market share.
- Regulatory changes in China could impact ETAO's operations and profitability.
- Economic slowdown in China could reduce demand for healthcare services.
- Fluctuations in the Chinese currency could impact ETAO's financial performance.
What Are the Growth Opportunities for ETAO?
- Expansion of AI-Driven Diagnostics: ETAO can leverage AI and big data to enhance diagnostic accuracy and efficiency. The global AI in healthcare market is projected to reach $95.7 billion by 2028, growing at a CAGR of 41.2%. ETAO's ability to integrate AI into its ecosystem could drive significant growth by providing more accurate and timely diagnoses, leading to better patient outcomes and increased demand for its services. Timeline: Ongoing.
- Integration of Specialized Clinics: ETAO's strategy of integrating specialized clinics into its ecosystem can attract patients seeking specialized medical care. The market for specialized medical services in China is growing rapidly, driven by increasing demand for high-quality healthcare. By offering a comprehensive range of specialized services, ETAO can differentiate itself from competitors and capture a larger share of the market. Timeline: Ongoing.
- Development of Biotechnology Companies: ETAO's involvement with biotechnology companies can lead to the development of innovative therapies and treatments. The global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a CAGR of 12.3%. By investing in biotechnology research and development, ETAO can create new revenue streams and enhance its reputation as a leading healthcare provider. Timeline: Ongoing.
- Growth of Insurance Agency: ETAO's insurance agency can play a crucial role in facilitating access to its healthcare services. The Chinese health insurance market is growing rapidly, driven by increasing awareness of the importance of health insurance. By offering tailored insurance products that cover its healthcare services, ETAO can attract more patients and increase its revenue. Timeline: Ongoing.
- Geographic Expansion within China: ETAO can expand its presence in China by establishing new hospitals and clinics in underserved areas. The Chinese healthcare market is highly fragmented, with significant disparities in access to healthcare services between urban and rural areas. By targeting underserved areas, ETAO can tap into a large and growing market. Timeline: Ongoing.
What Are ETAO's Competitive Advantages?
- Integrated Healthcare Ecosystem: ETAO's ecosystem of hospitals, clinics, AI diagnostics, and insurance creates a synergistic advantage.
- Focus on the Chinese Market: Deep understanding of the Chinese healthcare landscape and regulatory environment.
- Technology-Driven Innovation: Leveraging AI and big data to improve diagnostic accuracy and treatment efficiency.
What Does ETAO Do?
ETAO International Co., Ltd. is a digital healthcare company committed to delivering medical care and biomedical technologies to patients in China. The company is constructing a comprehensive healthcare ecosystem that integrates hospitals, specialized clinics, AI-driven diagnostics, medical analysis services, biotechnology companies, and an insurance agency. This ecosystem aims to provide patients with seamless access to a wide range of medical assistance and healthcare services. ETAO is based in New York, NY. The company's strategy focuses on leveraging technology to improve healthcare delivery and accessibility in the Chinese market. By combining traditional medical services with innovative technologies like AI and big data, ETAO seeks to enhance diagnostic accuracy, treatment efficiency, and patient outcomes. The insurance component of their ecosystem is designed to facilitate access to these services, addressing a critical need in the Chinese healthcare landscape. The company's approach is to create a vertically integrated platform that addresses various aspects of healthcare, from diagnosis to treatment and financial support.
What Products and Services Does ETAO Offer?
- Provides medical care to patients in China.
- Develops and integrates biomedical technologies.
- Designs and manages a healthcare ecosystem.
- Operates hospitals and specialized clinics.
- Offers AI/big data diagnostics.
- Provides medical analysis services.
- Works with biotechnology companies.
- Operates an insurance agency.
How Does ETAO Make Money?
- Generates revenue from medical services provided in its hospitals and clinics.
- Earns fees from AI-driven diagnostic services and medical analysis.
- Partners with biotechnology companies to develop and commercialize new therapies.
- Offers insurance products to facilitate access to its healthcare services.
What Industry Does ETAO Operate In?
ETAO International Co., Ltd. operates within the rapidly evolving healthcare information services industry. The industry is characterized by increasing demand for digital healthcare solutions, driven by factors such as an aging population, rising healthcare costs, and technological advancements. The Chinese healthcare market, in particular, presents significant opportunities due to its large population and increasing healthcare spending. However, the market is also highly competitive, with established players and new entrants vying for market share. ETAO's success will depend on its ability to differentiate itself through innovative solutions and effective execution.
Who Are ETAO's Key Customers?
- Patients seeking medical care in China.
- Individuals and families requiring health insurance.
- Healthcare providers utilizing AI-driven diagnostic tools.
- Biotechnology companies seeking partnerships for research and development.
How ETAO International Co., Ltd. Is Valued
ETAO International Co., Ltd. carries a market capitalization of $9.78M, placing it in the micro-cap category.
Company Profile
ETAO International Co., Ltd. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Wensheng Liu. ETAO has traded publicly since 2021.
Financial Health
ETAO International Co., Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
ETAO Financials
Bull Case vs Bear Case
Bull Case
- Integrated healthcare ecosystem.
- Focus on the large and growing Chinese market.
- Use of AI and big data for diagnostics.
- Insurance agency to facilitate access to services.
Bear Case
- Significant negative profit margin.
- Limited operating history.
- High beta indicating volatility.
- Dependence on the Chinese market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ETAO Latest News
No recent news available for ETAO.
Leadership: Wensheng Liu
CEO
Wensheng Liu is the CEO of ETAO International Co., Ltd. He is responsible for managing the company's overall strategy and operations, overseeing a workforce of 3600 employees. Information regarding his previous roles, education, and career history is not available in the provided data. His leadership is focused on expanding ETAO's presence in the Chinese healthcare market and building a comprehensive healthcare ecosystem.
Track Record: Due to limited information, it is not possible to assess Wensheng Liu's track record at ETAO International Co., Ltd. or in previous roles. His success will be measured by ETAO's ability to achieve profitability, expand its market share, and deliver innovative healthcare solutions.
ETAO International Co., Ltd. Healthcare Stock: Key Questions Answered
What happened to ETAO International Co., Ltd. (ETAO) stock?
ETAO International Co., Ltd. (ETAO) no longer trades on public markets. It was delisted in May 2024. The figures below are historical and are not a current quote.
Can I still buy ETAO shares?
No. ETAO stopped trading on public markets in May 2024, so the shares are not available through a broker. Anything you see quoted for ETAO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ETAO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ETAO International Co., Ltd.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does ETAO International Co., Ltd. do?
ETAO International Co., Ltd. is a digital healthcare company focused on providing medical care and biomedical technologies to patients in China. It is developing an integrated healthcare ecosystem that includes hospitals, specialized clinics, AI-driven diagnostics, medical analysis services, biotechnology partnerships, and an insurance agency. This ecosystem aims to provide comprehensive and accessible healthcare solutions to the Chinese market, leveraging technology to improve patient outcomes and efficiency.
What are ETAO International Co., Ltd.'s primary revenue streams in the healthcare sector?
ETAO International Co., Ltd.'s revenue streams are multifaceted, stemming from its integrated healthcare ecosystem. These include revenue generated from medical services provided at its hospitals and specialized clinics, fees from AI-driven diagnostic services and medical analysis, partnerships with biotechnology companies for developing and commercializing new therapies, and income from its insurance agency by providing coverage for its healthcare services.
What are the main risks for ETAO?
ETAO faces several key risks. Its significant negative profit margin raises concerns about its financial sustainability. The company operates in a highly competitive Chinese healthcare market, which could limit its ability to gain market share. Regulatory changes in China could impact its operations and profitability. An economic slowdown in China could reduce demand for healthcare services.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- AI analysis pending for ETAO, which could provide additional insights.
- Financial data based on available information and may not be comprehensive.